

FSCA Ref: FSN-2020-0004

Date: 13-May-2020

## <u>Urgent Field Safety Notice</u> <u>Thermo Scientific™ Oxoid™ DrySpot Staphytect Plus</u>

For Attention of\*: Lab Managers

Contact details of local representative (name, e-mail, telephone, address etc.)\*

mbd.vigilance@thermofisher.com

Fax: +44(0)1256 334 994



FSCA Ref: FSN-2020-0004

# Urgent Field Safety Notice (FSN) Thermo Scientific™ Oxoid™ DrySpot Staphytect Plus Risk addressed by FSN

1. Information on Affected Devices*				
1	1.	Device Type(s)*		
		IVD		
1	2.	Commercial name(s)		
		Thermo Scientific Oxoid DrySpot Staphytect Plus		
1	3.	Unique Device Identifier(s) (UDI-DI)		
		05032384029297		
1	4.	Primary clinical purpose of device(s)*		
		DrySpot Staphytect Plus™ is a latex slide agglutination test for the differentiation		
		of Staphylococcus aureus by detection of clumping factor, Protein A and certain		
		polysaccharides found in methicillin- resistant S. aureus (MRSA) from those		
		staphylococci that do not possess these properties.		
1	5.	Device Model/Catalogue/part number(s)*		
		DR0100M		
1	6.	Software version		
		N/A		
1	7.	Affected serial or lot number range		
		2916980		
1	8.	Associated devices		
		N/A		




Rev 1: September 2018 FSN Ref: FSN-2020-0004 FSCA Ref: FSN-2020-0004

## 2 Reason for Field Safety Corrective Action (FSCA)\*

2 1. Description of the product problem\*

An internal technical investigation has determined that Thermo Scientific™ Oxoid™ DrySpot Staphytect Plus (DR0100M) may show variable levels of granularity with the Test Reagent, before the recommended read end time, as illustrated in the photograph below.



- 2 2. Hazard giving rise to the FSCA\*
  - This granularity may be misinterpreted as a positive result when used according to the Instructions For Use (IFU).
- 2 3. Probability of problem arising
- High
- 2 4. Predicted risk to patient/users
- The clinical consequence of a false positive result could potentially result in unwarranted antimicrobial therapy and a potential delay in getting the correct therapy.
- 2 5. Further information to help characterise the problem
  - None
- 2 6. Background on Issue
- . Internal investigation following Quality Control failure of product release for second part of split batch.
- 2 7. Other information relevant to FSCA
- . 2916980 Expiry 30-Apr-2022



FSCA Ref: FSN-2020-0004

	3. Type of Action to mitigate the risk*						
3.	1.	Action To Be Taken by	the User*				
			antine Device   Return	Device   Destroy Device			
		☐ On-site device modification/inspection					
		☐ Follow patient management recommendations					
		☐ Take note of amendment/reinforcement of Instructions For Use (IFU)					
		□ Other □ None	<b>;</b>				
3.	2.	Py when should the	Immediately				
ა.	۷.	By when should the action be completed?	miniculatery				
3.	3.	. Particular considerations for: IVD					
		Is follow-up of patients or review of patients' previous results recommended?					
		Yes	eview of patients previous	results recommended?			
		res					
		We request that the requirement for review of reported test results should be					
	_	determined by the appropri					
3.	4.			Yes			
3.		yes, form attached specifyin					
ა.	ວ.	Action Being Taken by	the Manufacturer				
		□ Product Removal     □	On-site device modification/	inspection			
			IFU or labelling change	op code			
			□ None				
3	6.	By when should the					
		action be completed?					
3.	7.	Is the FSN required to be o	ommunicated to the patien	t No			
		/lay user?	21 1 192 127 2	7.11.6.0			
3		8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?					
3	ο.						



FSCA Ref: FSN-2020-0004

	4. General Information*				
4.	1. FSN Type*	New			
4.	For updated FSN, reference number and date of previous FSN	N/A			
4.	3. For Updated FSN, key new information as follows:				
	N/A				
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet			
4	If follow-up FSN expected, what is the further advice expected to relate to:  N/A				
4	Anticipated timescale for follow- up FSN	N/A			
4.	7. Manufacturer information				
	(For contact details of local representative	refer to page 1 of this FSN)			
	a. Company Name	Thermo Fisher Scientific			
	b. Address	Wade Road, Basingstoke,			
		Hampshire			
		RG24 8PW			
	c. Website address	www.thermofisher.com			
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *				
4.	9. List of attachments/appendices:	Customer Response Form			
4.	10. Name	James Filer			
	Signature	Janus A			

#### **Transmission of this Field Safety Notice**

This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)

Please transfer this notice to other organisations on which this action has an impact. (As appropriate)

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.\*



FSCA Ref: FSN-2020-0004

#### **Customer Reply Form**

1. Field Safety Notice (FSN) information					
FSN Reference number*			FSN-2020-0004		
FSN [			13 <sup>th</sup> May 2020		
Produ	ct/ Device name*		Thermo Scientific™ Oxoid™ Dryspot Staphytect		
			Plus		
Produ	ct Code(s)		DR0100M		
Batch	/Serial Number (s)		2916980		
2. C	ustomer Details				
	ınt Number				
	isation Name*				
	isation Address*				
	tment/Unit				
	ing address if different to above	Э			
	ct Name*				
	r Function				
	hone number*				
Email'					
3. C	ustomer action undertaken o	n behalf of H	ealthcare Organisation		
	I confirm receipt of the Field				
	Safety Notice and that I				
	read and understood its				
	content.				
	I performed all actions				
	requested by the FSN.				
	The information and				
	required actions have been				
	brought to the attention of all relevant users and				
	executed.				
	I have destroyed affected	Qty:	Lot/Serial Number:		
	devices – enter number	Date:	Comments: Credit ☐ Replacement ☐		
	destroyed and date	Date.	Comments. Credit — Replacement —		
	complete.				
	No affected devices are				
	available for destruction				
	I have a query please				
	contact me				
	(e.g. need for replacement of the				
Drint N	product). Name*				
Plintr	vame				
Signature*					
Signa	tuie				
Date*					
4. Return acknowledgement to sender					
Email mbd.vigilance@thermofisher.com					
Custo	mer Services Tel. & Fax		Fax: +44(0)1256 334 994		
Deadline for returning the reply form*			9th June 2020		

Mandatory fields are marked with \*

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.